|9 Months Ended|
Apr. 30, 2017
|Subsequent Events [Abstract]|
Note 11—Subsequent Events
On May 10, 2017, the Company entered into a clinical trial collaboration and supply agreement with MSD International GmbH, a subsidiary of Merck & Co., Inc. (“Merck”) to clinically evaluate the combination of ImmunoPulse® IL-12 with Merck’s anti PD-1 therapy KEYTRUDA® (pembrolizumab). Under this agreement, the Company will sponsor and fund the Phase II multicenter study of ImmunoPulse® IL-12 in combination with KEYTRUDA® in patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV, who are progressing or have progressed on an approved anti-PD-1 therapy. Merck will be responsible for manufacturing and supplying KEYTRUDA® for this study.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/presentationRef